ZA202305122B - Prophylaxis and treatment of angioedema - Google Patents

Prophylaxis and treatment of angioedema

Info

Publication number
ZA202305122B
ZA202305122B ZA2023/05122A ZA202305122A ZA202305122B ZA 202305122 B ZA202305122 B ZA 202305122B ZA 2023/05122 A ZA2023/05122 A ZA 2023/05122A ZA 202305122 A ZA202305122 A ZA 202305122A ZA 202305122 B ZA202305122 B ZA 202305122B
Authority
ZA
South Africa
Prior art keywords
treatment
angioedema
human patient
alleviate
symptoms
Prior art date
Application number
ZA2023/05122A
Other languages
English (en)
Inventor
LESAGE Anne
Lu Peng
Original Assignee
Pharvaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharvaris Gmbh filed Critical Pharvaris Gmbh
Publication of ZA202305122B publication Critical patent/ZA202305122B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2023/05122A 2020-11-12 2023-05-09 Prophylaxis and treatment of angioedema ZA202305122B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20207273 2020-11-12
PCT/EP2021/081493 WO2022101395A1 (en) 2020-11-12 2021-11-12 Prophylaxis and treatment of angioedema

Publications (1)

Publication Number Publication Date
ZA202305122B true ZA202305122B (en) 2024-08-28

Family

ID=73401436

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2023/05122A ZA202305122B (en) 2020-11-12 2023-05-09 Prophylaxis and treatment of angioedema

Country Status (13)

Country Link
US (1) US12629363B2 (cg-RX-API-DMAC7.html)
EP (1) EP4243824B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023549849A (cg-RX-API-DMAC7.html)
KR (1) KR20230107269A (cg-RX-API-DMAC7.html)
CN (1) CN116685353A (cg-RX-API-DMAC7.html)
AU (1) AU2021376885A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198246A1 (cg-RX-API-DMAC7.html)
ES (1) ES3061585T3 (cg-RX-API-DMAC7.html)
IL (1) IL302887A (cg-RX-API-DMAC7.html)
MX (1) MX2023005563A (cg-RX-API-DMAC7.html)
PL (1) PL4243824T3 (cg-RX-API-DMAC7.html)
WO (1) WO2022101395A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202305122B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202345810A (zh) * 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽b2受體拮抗劑之固態延長釋放組成物
HRP20260166T1 (hr) * 2022-03-25 2026-03-27 Pharvaris Gmbh Čvrsti sastav koji sadrži solubilizirane antagoniste bradikinin b2 receptora
EP4745196A1 (en) 2023-08-16 2026-05-20 LG Chem, Ltd. RESIN COMPOSITION

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080249076A1 (en) 2003-12-03 2008-10-09 Lifecycle Pharma A/S Pharmaceutical Compositions Comprising Danazol
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽b2受體調節劑
AR073304A1 (es) 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
US7816383B1 (en) 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
KR20150127718A (ko) 2013-03-14 2015-11-17 샤이어 휴먼 지네틱 테라피즈 인크. B2-브라디키닌 수용체 매개 혈관부종의 치료 방법
SMT202200154T1 (it) * 2017-11-24 2022-05-12 Pharvaris Netherlands B V Nuovi antagonisti del recettore della bradichinina b2
UY38706A (es) 2019-05-23 2020-12-31 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
AR118983A1 (es) 2019-05-23 2021-11-17 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina

Also Published As

Publication number Publication date
KR20230107269A (ko) 2023-07-14
JP2023549849A (ja) 2023-11-29
CN116685353A (zh) 2023-09-01
ES3061585T3 (en) 2026-04-06
WO2022101395A1 (en) 2022-05-19
EP4243824C0 (en) 2025-12-24
US20230338358A1 (en) 2023-10-26
IL302887A (en) 2023-07-01
PL4243824T3 (pl) 2026-05-18
MX2023005563A (es) 2023-09-11
EP4243824B1 (en) 2025-12-24
AU2021376885A1 (en) 2023-06-08
CA3198246A1 (en) 2022-05-19
US12629363B2 (en) 2026-05-19
EP4243824A1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
MX2023005563A (es) Profilaxis y tratamiento del angioedema.
NZ572049A (en) Method for treatment of constipation-predominant irritable bowel syndrome
MX2023013403A (es) Composicion farmaceutica para prevenir o tratar la fibrosis.
EP4647125A3 (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
MX2022011490A (es) Tratamiento o metodo de prevencion de falla cardiaca cronica.
WO2021007314A3 (en) Treatment of cancer
MX2024011142A (es) Tratamiento de neurofibromas cutaneos con mirdametinib.
MX2022015760A (es) Inhibidor del receptor tipo toll 7 (tlr7) en combinacion con prednisolona o hidroxicloroquina para el tratamiento del lupus eritematoso cutaneo.
MX2022012135A (es) Métodos para tratar la enfermedad de coronavirus de 2019.
MX2022011725A (es) Metodos para tratar una lesion pulmonar con inhibidores de cgrp.
MX2025000673A (es) Metodos de administracion de nalbufina
WO2016090107A3 (en) Treatment of hepatitis delta virus infection
MX2022004785A (es) Metodos y composiciones para el tratamiento del sindrome de rett.
MX2022015146A (es) Tratamiento de la artritis reumatoide.
JOP20230147A1 (ar) معالجة اعتلال كبيبات الكلى c3 باستخدام مثبط c5a
MX2008016520A (es) Medicamentos.
MX2025007194A (es) Antagonistas del receptor 1 del acido lisofosfatidico (lpa1) para el tratamiento de la enfermedad pulmonar intersticial
WO2020025657A9 (en) Composition for use in the prevention and/or treatment of the genitourinary mucosa
ZA202407245B (en) Novel use of pitolisant for treating severe fatigue
MY203365A (en) Montelukast for the treatment of erosive hand osteoarthritis
PH12021550134A1 (en) Therapeutic or prophylactic agent for htlv-1-associated myelopathy (ham), and method for treating ham
WO2011008490A3 (en) Combination therapies for the treatment of obesity
WO2022251752A3 (en) Dual treatment of migraine
WO2022048618A8 (en) Methods to treat inflammatory bowel disease